Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis

Findings From the CureGN Study

CureGN Consortium

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: The Cure Glomerulonephropathy Network (CureGN) is a 66-center longitudinal observational study of patients with biopsy-confirmed minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy (IgAN), including IgA vasculitis (IgAV). This study describes the clinical characteristics and treatment patterns in the IgA cohort, including comparisons between IgAN versus IgAV and adult versus pediatric patients. Methods: Patients with a diagnostic kidney biopsy within 5 years of screening were eligible to join CureGN. This is a descriptive analysis of clinical and treatment data collected at the time of enrollment. Results: A total of 667 patients (506 IgAN, 161 IgAV) constitute the IgAN/IgAV cohort (382 adults, 285 children). At biopsy, those with IgAV were younger (13.0 years vs. 29.6 years, P < 0.001), more frequently white (89.7% vs. 78.9%, P = 0.003), had a higher estimated glomerular filtration rate (103.5 vs. 70.6 ml/min per 1.73 m2, P < 0.001), and lower serum albumin (3.4 vs. 3.8 g/dl, P < 0.001) than those with IgAN. Adult and pediatric individuals with IgAV were more likely than those with IgAN to have been treated with immunosuppressive therapy at or prior to enrollment (79.5% vs. 54.0%, P < 0.001). Conclusion: This report highlights clinical differences between IgAV and IgAN and between children and adults with these diagnoses. We identified differences in treatment with immunosuppressive therapies by disease type. This description of baseline characteristics will serve as a foundation for future CureGN studies.

Original languageEnglish (US)
Pages (from-to)1373-1384
Number of pages12
JournalKidney International Reports
Volume3
Issue number6
DOIs
StatePublished - Nov 1 2018

Fingerprint

Vasculitis
Immunoglobulin A
Therapeutics
Immunosuppressive Agents
Biopsy
Pediatrics
Lipoid Nephrosis
Focal Segmental Glomerulosclerosis
Membranous Glomerulonephritis
Glomerular Filtration Rate
Serum Albumin
Observational Studies
Longitudinal Studies

Keywords

  • glomerulonephritis
  • Henoch-Schönlein purpura (HSP)
  • IgA nephropathy (IgAN)
  • IgA vasculitis (IgAV)

ASJC Scopus subject areas

  • Nephrology

Cite this

Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis : Findings From the CureGN Study. / CureGN Consortium.

In: Kidney International Reports, Vol. 3, No. 6, 01.11.2018, p. 1373-1384.

Research output: Contribution to journalArticle

@article{f9e6dda200b04833b7c2f710c74f159f,
title = "Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study",
abstract = "Introduction: The Cure Glomerulonephropathy Network (CureGN) is a 66-center longitudinal observational study of patients with biopsy-confirmed minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy (IgAN), including IgA vasculitis (IgAV). This study describes the clinical characteristics and treatment patterns in the IgA cohort, including comparisons between IgAN versus IgAV and adult versus pediatric patients. Methods: Patients with a diagnostic kidney biopsy within 5 years of screening were eligible to join CureGN. This is a descriptive analysis of clinical and treatment data collected at the time of enrollment. Results: A total of 667 patients (506 IgAN, 161 IgAV) constitute the IgAN/IgAV cohort (382 adults, 285 children). At biopsy, those with IgAV were younger (13.0 years vs. 29.6 years, P < 0.001), more frequently white (89.7{\%} vs. 78.9{\%}, P = 0.003), had a higher estimated glomerular filtration rate (103.5 vs. 70.6 ml/min per 1.73 m2, P < 0.001), and lower serum albumin (3.4 vs. 3.8 g/dl, P < 0.001) than those with IgAN. Adult and pediatric individuals with IgAV were more likely than those with IgAN to have been treated with immunosuppressive therapy at or prior to enrollment (79.5{\%} vs. 54.0{\%}, P < 0.001). Conclusion: This report highlights clinical differences between IgAV and IgAN and between children and adults with these diagnoses. We identified differences in treatment with immunosuppressive therapies by disease type. This description of baseline characteristics will serve as a foundation for future CureGN studies.",
keywords = "glomerulonephritis, Henoch-Sch{\"o}nlein purpura (HSP), IgA nephropathy (IgAN), IgA vasculitis (IgAV)",
author = "{CureGN Consortium} and Selewski, {David T.} and Ambruzs, {Josephine M.} and Appel, {Gerald B.} and Bomback, {Andrew S.} and Matar, {Raed Bou} and Yi Cai and Cattran, {Daniel C.} and Chishti, {Aftab S.} and D'Agati, {Vivette D.} and D'Alessandri-Silva, {Cynthia J.} and Gbadegesin, {Rasheed A.} and Hogan, {Jonathan J.} and Sandra Iragorri and Jennette, {J. Charles} and Julian, {Bruce A.} and Myda Khalid and Lafayette, {Richard A.} and Helen Liapis and Francesca Lugani and Mansfield, {Sarah A.} and Sherene Mason and Nachman, {Patrick H.} and Nast, {Cynthia C.} and Nester, {Carla M.} and Noone, {Damien G.} and Jan Novak and O'Shaughnessy, {Michelle M.} and Reich, {Heather N.} and Rheault, {Michelle N.} and Rizk, {Dana V.} and Saha, {Manish K.} and Sanghani, {Neil S.} and Sperati, {C. John} and Rajasree Sreedharan and Tarak Srivastava and Agnieszka Swiatecka-Urban and Katherine Twombley and Vasylyeva, {Tetyana L.} and Weaver, {Donald J.} and Hong Yin and Jarcy Zee and Falk, {Ronald J.} and Gharavi, {Ali G.} and Gillespie, {Brenda W.} and Gipson, {Debbie S.} and Greenbaum, {Larry A.} and Holzman, {Lawrence B.} and Matthias Kretzler and Robinson, {Bruce M.} and Amira Al-Uzri",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.ekir.2018.07.021",
language = "English (US)",
volume = "3",
pages = "1373--1384",
journal = "Kidney International Reports",
issn = "2468-0249",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis

T2 - Findings From the CureGN Study

AU - CureGN Consortium

AU - Selewski, David T.

AU - Ambruzs, Josephine M.

AU - Appel, Gerald B.

AU - Bomback, Andrew S.

AU - Matar, Raed Bou

AU - Cai, Yi

AU - Cattran, Daniel C.

AU - Chishti, Aftab S.

AU - D'Agati, Vivette D.

AU - D'Alessandri-Silva, Cynthia J.

AU - Gbadegesin, Rasheed A.

AU - Hogan, Jonathan J.

AU - Iragorri, Sandra

AU - Jennette, J. Charles

AU - Julian, Bruce A.

AU - Khalid, Myda

AU - Lafayette, Richard A.

AU - Liapis, Helen

AU - Lugani, Francesca

AU - Mansfield, Sarah A.

AU - Mason, Sherene

AU - Nachman, Patrick H.

AU - Nast, Cynthia C.

AU - Nester, Carla M.

AU - Noone, Damien G.

AU - Novak, Jan

AU - O'Shaughnessy, Michelle M.

AU - Reich, Heather N.

AU - Rheault, Michelle N.

AU - Rizk, Dana V.

AU - Saha, Manish K.

AU - Sanghani, Neil S.

AU - Sperati, C. John

AU - Sreedharan, Rajasree

AU - Srivastava, Tarak

AU - Swiatecka-Urban, Agnieszka

AU - Twombley, Katherine

AU - Vasylyeva, Tetyana L.

AU - Weaver, Donald J.

AU - Yin, Hong

AU - Zee, Jarcy

AU - Falk, Ronald J.

AU - Gharavi, Ali G.

AU - Gillespie, Brenda W.

AU - Gipson, Debbie S.

AU - Greenbaum, Larry A.

AU - Holzman, Lawrence B.

AU - Kretzler, Matthias

AU - Robinson, Bruce M.

AU - Al-Uzri, Amira

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Introduction: The Cure Glomerulonephropathy Network (CureGN) is a 66-center longitudinal observational study of patients with biopsy-confirmed minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy (IgAN), including IgA vasculitis (IgAV). This study describes the clinical characteristics and treatment patterns in the IgA cohort, including comparisons between IgAN versus IgAV and adult versus pediatric patients. Methods: Patients with a diagnostic kidney biopsy within 5 years of screening were eligible to join CureGN. This is a descriptive analysis of clinical and treatment data collected at the time of enrollment. Results: A total of 667 patients (506 IgAN, 161 IgAV) constitute the IgAN/IgAV cohort (382 adults, 285 children). At biopsy, those with IgAV were younger (13.0 years vs. 29.6 years, P < 0.001), more frequently white (89.7% vs. 78.9%, P = 0.003), had a higher estimated glomerular filtration rate (103.5 vs. 70.6 ml/min per 1.73 m2, P < 0.001), and lower serum albumin (3.4 vs. 3.8 g/dl, P < 0.001) than those with IgAN. Adult and pediatric individuals with IgAV were more likely than those with IgAN to have been treated with immunosuppressive therapy at or prior to enrollment (79.5% vs. 54.0%, P < 0.001). Conclusion: This report highlights clinical differences between IgAV and IgAN and between children and adults with these diagnoses. We identified differences in treatment with immunosuppressive therapies by disease type. This description of baseline characteristics will serve as a foundation for future CureGN studies.

AB - Introduction: The Cure Glomerulonephropathy Network (CureGN) is a 66-center longitudinal observational study of patients with biopsy-confirmed minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy (IgAN), including IgA vasculitis (IgAV). This study describes the clinical characteristics and treatment patterns in the IgA cohort, including comparisons between IgAN versus IgAV and adult versus pediatric patients. Methods: Patients with a diagnostic kidney biopsy within 5 years of screening were eligible to join CureGN. This is a descriptive analysis of clinical and treatment data collected at the time of enrollment. Results: A total of 667 patients (506 IgAN, 161 IgAV) constitute the IgAN/IgAV cohort (382 adults, 285 children). At biopsy, those with IgAV were younger (13.0 years vs. 29.6 years, P < 0.001), more frequently white (89.7% vs. 78.9%, P = 0.003), had a higher estimated glomerular filtration rate (103.5 vs. 70.6 ml/min per 1.73 m2, P < 0.001), and lower serum albumin (3.4 vs. 3.8 g/dl, P < 0.001) than those with IgAN. Adult and pediatric individuals with IgAV were more likely than those with IgAN to have been treated with immunosuppressive therapy at or prior to enrollment (79.5% vs. 54.0%, P < 0.001). Conclusion: This report highlights clinical differences between IgAV and IgAN and between children and adults with these diagnoses. We identified differences in treatment with immunosuppressive therapies by disease type. This description of baseline characteristics will serve as a foundation for future CureGN studies.

KW - glomerulonephritis

KW - Henoch-Schönlein purpura (HSP)

KW - IgA nephropathy (IgAN)

KW - IgA vasculitis (IgAV)

UR - http://www.scopus.com/inward/record.url?scp=85055727446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055727446&partnerID=8YFLogxK

U2 - 10.1016/j.ekir.2018.07.021

DO - 10.1016/j.ekir.2018.07.021

M3 - Article

VL - 3

SP - 1373

EP - 1384

JO - Kidney International Reports

JF - Kidney International Reports

SN - 2468-0249

IS - 6

ER -